Scinai Immunotherapeutics (SCNI) Income from Continuing Operations (2014 - 2026)
Scinai Immunotherapeutics (SCNI) reported Income from Continuing Operations of 2467000.0 for Q1 2026, down 57.33% on a YoY basis from 5782146.49 in Q1 2025, and down 12.39% sequentially from 2195000.0 in Q2 2025.
Scinai Immunotherapeutics (SCNI) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Scinai Immunotherapeutics (SCNI) has 13 years of Income from Continuing Operations data on file, last reported at 2467000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 57.33% year-over-year to 2467000.0; the trailing twelve-month figure through Mar 2026 stood at 9866000.0 (up 26.96% YoY), and the FY2025 full-year result was 38262000.0, down 18.32% from the prior year.
- Income from Continuing Operations eased to 2467000.0 in Q1 2026, from 2195000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 3611000.0 in Q2 2023 to a low of 19777000.0 in Q4 2022.
- A 5-year average of 2844800.0 and a median of 2420000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations jumped 327.21% in 2023 and slumped 262.92% in 2024, its largest moves.
- Tracing SCNI's Income from Continuing Operations over 5 years: stood at 19777000.0 in 2022, then jumped by 90.24% to 1931000.0 in 2023, then sank by 88.3% to 3636000.0 in 2024, then surged by 39.63% to 2195000.0 in 2025, then fell by 12.39% to 2467000.0 in 2026.
- Business Quant data shows SCNI's Income from Continuing Operations at 2467000.0 in Q1 2026, 2195000.0 in Q2 2025, and 1568000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Scinai Immunotherapeutics | 3.54 Bn | 424.15 Mn | -1.12 Mn | -2.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.47 Mn |
| Jun 30, 2025 | -2.20 Mn |
| Mar 31, 2025 | -1.57 Mn |
| Dec 31, 2024 | -3.64 Mn |
| Sep 30, 2024 | -2.42 Mn |
| Jun 30, 2024 | -5.88 Mn |
| Mar 31, 2024 | 2.16 Mn |
| Dec 31, 2023 | -1.93 Mn |
| Sep 30, 2023 | -3.11 Mn |
| Jun 30, 2023 | 3.61 Mn |
| Mar 31, 2023 | 3.40 Mn |
| Dec 31, 2022 | -19.78 Mn |
| Sep 30, 2022 | -4.37 Mn |
| Jun 30, 2022 | -3.00 Mn |
| Mar 31, 2022 | -1.50 Mn |
| Dec 31, 2021 | 12.39 Mn |
| Sep 30, 2021 | -3.44 Mn |
| Jun 30, 2021 | -6.17 Mn |
| Mar 31, 2021 | -888,000.00 |
| Dec 31, 2020 | -16.51 Mn |